Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/07/31 Updated
Market Cap: $33.2B (¥5.3T)
Stock Price: $18.23 (¥2,889)
Exchange Rate: 1 USD = ¥158.48

Financial Summary: Overview and Business Trends for Q1 FY2026

Net sales for Q1 FY2026 were ¥474.6 billion (down 24.6% YoY), with operating income unknown. The overseas sales ratio was 69.2%. Currency exchange effects are also considered.

Importance:
Page Updated: July 31, 2026
IR Disclosure Date: July 31, 2026

Key Figures

  • Net Sales: ¥474.6 billion (Down 24.6% YoY)
  • Net Income Attributable to Owners of the Parent: ¥85.5 billion (+18.0%)
  • Overseas Sales Ratio: 69.2%

AI要約

Performance Overview

Net sales for Q1 FY2026 amounted to ¥474.6 billion, decreasing 24.6% compared to the same period last year. The overseas sales ratio reached 69.2%, with currency exchange effects also taken into account. Details on operating income and net income are not specified, but net income attributable to the parent increased to ¥85.5 billion compared to the same quarter last year. Detailed segment-wise data showing trends in sales and profits are included.

Future Outlook and Corporate Activities

The document lacks specific forecasts or mid-term plans, so continued detailed analysis of quarterly results and currency exchange impacts remains important. Information regarding capital policies, new product launches, or M&A activities is not included, so attention should be given to upcoming financial results and mid-term plans.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Daiichi Sankyo

Company overview · Stock price · Financial data · All IR

View company page →